NCT00323739 - Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

March 31, 2011

Conditions

Kidney Cancer

Interventions

DRUG

bevacizumab

Bevacizumab 10mg/kg, IV infusion, every 2 weeks

DRUG

RAD001

RAD001 10 mg by mouth daily

Trial Locations (12)

Wellstar Cancer Research, Marietta

Integrated Community Oncology Network, Jacksonville

Gainsville Hematology Oncology Associates, Gainesville

Florida Hospital Cancer Institute, Orlando

Florida Cancer Specialists, Fort Myers

Tennessee Oncology, PLLC, Nashville

Chattanooga Oncology Hematology Associates, Chattanooga

Consultants in Blood Disorders and Cancer, Louisville

Oncology Hematology Care, Cincinnati

Grand Rapids Clinical Oncology Program, Grand Rapids

Methodist Cancer Center, Omaha

Baton Rouge General Medical Center, Baton Rouge